FUT7

Alpha-(1,3)-fucosyltransferase 7 · Q11130 · FUT7 on Sugi Atlas →

8,923 patent compounds predicted against FUT7, 6,011 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gallic Acid (SCHEMBL15012)	1.00	2/20
Gallic Acid Methyl Ester (SCHEMBL39513)	1.00	2/20
Gallic Acid (SCHEMBL678990)	1.00	2/20
Gallic Acid (SCHEMBL109154)	0.94	2/20
Gallic Acid (SCHEMBL135340)	0.94	2/20
Gallic Acid (SCHEMBL154210)	0.94	2/20
Gallic Acid (SCHEMBL210236)	0.94	2/20
Gallic Acid (SCHEMBL338356)	0.94	2/20
Gallic Acid (SCHEMBL438023)	0.94	2/20
Gallic Acid (SCHEMBL597299)	0.94	2/20
Gallic Acid (SCHEMBL617139)	0.94	2/20
Gallic Acid (SCHEMBL702575)	0.94	2/20
Gallic Acid (SCHEMBL990972)	0.94	2/20
Gallic Acid (SCHEMBL1060587)	0.94	2/20
Gallic Acid (SCHEMBL1065001)	0.94	2/20
Gallic Acid (SCHEMBL1033794)	0.90	2/20
Digallic Acid (SCHEMBL39415)	0.65	2/20
SCHEMBL352369	0.65	2/20
SCHEMBL975675	0.64	2/20
SCHEMBL407763	0.62	2/20

Clinical trials — most relevant to FUT7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study	PHASE4	COMPLETED
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia	PHASE1/PHASE2	RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL	PHASE1/PHASE2	RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma	PHASE1/PHASE2	WITHDRAWN
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells	PHASE1/PHASE2	RECRUITING
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies	PHASE1/PHASE2	RECRUITING
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL	PHASE2	RECRUITING
Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy	PHASE1/PHASE2	UNKNOWN
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant	PHASE1	RECRUITING
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)	PHASE1	WITHDRAWN
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption	PHASE1	COMPLETED
Universal 4SCAR7U Targeting CD7-positive Malignancies	PHASE1	RECRUITING
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS	PHASE1	RECRUITING
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	PHASE1	UNKNOWN
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells	PHASE1	COMPLETED
The Correlation of Lewis Antigens With VTE	nan	NOT_YET_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)	nan	COMPLETED
Study of Blood Immune Cells in Cancer Patients Compared to Controls	nan	UNKNOWN
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies	nan	NOT_YET_RECRUITING
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FUT7 binder may also engage these)

Protein	Name	Similarity
G3MZR2	—	0.999	G3MZR2 →
Q712G6	—	0.993	Q712G6 →
Q8HZR3	—	0.989	Q8HZR3 →
Q11131	—	0.987	Q11131 →
Q8HYJ3	—	0.986	Q8HYJ3 →
P56434	—	0.985	P56434 →
P56433	—	0.984	P56433 →
Q62994	—	0.983	Q62994 →
Q8HYJ5	—	0.983	Q8HYJ5 →
Q8HYJ4	—	0.983	Q8HYJ4 →
Q8HYJ6	—	0.982	Q8HYJ6 →
FUT5	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5	0.982	landscape →
P21217	—	0.982	P21217 →
Q9GKU6	—	0.980	Q9GKU6 →
O19058	—	0.979	O19058 →
FUT6	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6	0.977	landscape →
Q8HYJ7	—	0.977	Q8HYJ7 →
Q11127	—	0.976	Q11127 →
Q11126	—	0.974	Q11126 →
Q8N3Y3	—	0.966	Q8N3Y3 →
Q92935	—	0.960	Q92935 →
O09008	—	0.957	O09008 →
Q6IQX7	—	0.957	Q6IQX7 →
FUT4	Alpha-(1,3)-fucosyltransferase 4	0.956	landscape →
Q91Z92	—	0.956	Q91Z92 →
Q866F1	—	0.956	Q866F1 →
SMPD1	Sphingomyelin phosphodiesterase	0.956	landscape →
Q659K9	—	0.956	Q659K9 →
Q5T4B2	—	0.956	Q5T4B2 →
P15589	—	0.955	P15589 →